Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aubagio

- PMLiVE

Second Sarclisa combination regimen for multiple myeloma approved in EU

Second indication for Sarclisa covers drug’s use in combination with another standard myeloma treatment

Novartis day

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

New post hoc data comes from phase 3 ASCLEPIOS trials

- PMLiVE

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

Checkpoint inhibitor plus tyrosine kinase inhibitor approved for the first-line treatment of advanced renal cell carcinoma

- PMLiVE

UPDATE: AZ/Oxford University COVID-19 vaccine gets EU approval

MHRA is looking "very closely" at reports of adverse reactions to coronavirus vaccines

- PMLiVE

Sanofi pays $160m upfront to acquire Tidal Therapeutics

French pharma company's acquisition of pre-clinical stage biotech includes mRNA-based research platform

Roche Basel Switzerland

EU authorises Roche’s spinal muscular atrophy treatment Evrysdi

First SMA treatment approved in the EU that can be taken at home

- PMLiVE

Novartis gains EU approval for relapsing MS drug Kesimpta

The drug reduces the number of confirmed relapses in MS patients

- PMLiVE

J&J’s multiple sclerosis therapy Ponvory moves closer to EU approval

CHMP issues a positive opinion for S1P1 modulator based on positive phase 3 results

- PMLiVE

EU leaders debate COVID-19 vaccine export measures during virtual summit

AstraZeneca urged to ‘honour’ contract with EU before exporting doses elsewhere

- PMLiVE

EU, UK working towards a ‘win-win’ situation to expand COVID-19 vaccine supplies

EU leaders are set to meet today to discuss proposed vaccine export plans

- PMLiVE

EU-UK COVID-19 vaccine row continues as export ban discussion looms

EU officials are set to discuss imposing a vaccine export ban this week

- PMLiVE

J&J’s MS drug ponesimod receives approval in the US

US regulator has approved the drug – now named Ponvory – for relapsing forms of MS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links